Compare RPD & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPD | IOVA |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 968.6M |
| IPO Year | 2015 | N/A |
| Metric | RPD | IOVA |
|---|---|---|
| Price | $15.40 | $2.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 12 |
| Target Price | ★ $24.00 | $10.45 |
| AVG Volume (30 Days) | 1.1M | ★ 11.3M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $858,667,000.00 | $250,425,000.00 |
| Revenue This Year | $2.62 | $60.71 |
| Revenue Next Year | $1.49 | $59.52 |
| P/E Ratio | $44.24 | ★ N/A |
| Revenue Growth | 3.08 | ★ 175.62 |
| 52 Week Low | $13.21 | $1.64 |
| 52 Week High | $41.38 | $8.15 |
| Indicator | RPD | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 69.24 |
| Support Level | $15.06 | $2.08 |
| Resistance Level | $15.90 | $2.60 |
| Average True Range (ATR) | 0.46 | 0.17 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 15.93 | 87.36 |
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.